Skip to main content

Table 2 Clinical cure rates at test-of-cure visit

From: A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]

  Tigecycline Imipenem/cilastatin Difference Tigecycline-Imipenem/cilastatin Test for Noninferiority Test for Differences
Population N % (95% CI) N % (95% CI) % (95% CI) P value  
CE 282/341 82.7 (78.3, 86.6) 295/351 84.0 (79.8, 87.7) -1 (-7.2, 4.5) <0.0001 0.70
   Overall        -1 (-6.9, 4.2)*
c-mITT 303/408 74.3 (69.7, 78.4) 317/399 79.4 (75.1, 83.3) -5 (-11.2, 0.0) <0.0001 0.00
   Overall        -5 (-11.0, 0.0)
ME 199/247 80.6 (75.1, 85.3) 210/255 82.4 (77.1, 86.8) -1.8 (-9.0, 5.4) 0.0001 0.6892
   Monomicrobial 80/89 89.9 (81.7, 95.3) 92/104 88.5 (80.7, 93.9) 1.4 (-8.7, 11.0)   
   Polymicrobial 119/158 75.3 (67.8, 81.8) 118/151 78.1 (70.7, 84.5) -2.8 (-12.6, 7.1)   
   Overall        -1.7 (-8.4, 5.1)*
m-mITT 227/309 73.5 (68.2, 78.3) 244/312 78.2 (73.2, 82.7) -4.7 (-11.8, 2.3) 0.0019 0.1976
   Monomicrobial 96/121 79.3 (71.0, 86.2) 109/128 85.2 (77.8, 90.8) -5.8 (-15.9, 4.3)   
   Polymicrobial 131/188 69.7 (62.6, 76.2) 135/184 73.4 (66.4, 79.6) -3.7 (-13.1, 5.9)   
   Overall        -4.3 (-11.0, 2.5)*
  1. *Adjusted difference and its 95%CI are calculated from a generalized linear model with a binomial probability function and an identity link.